Arcus Biosciences Inc
NYSE:RCUS
Arcus Biosciences Inc
Interest Income Expense
Arcus Biosciences Inc
Interest Income Expense Peer Comparison
Competitive Interest Income Expense Analysis
Latest Figures & CAGR of Competitors
Company | Interest Income Expense | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Arcus Biosciences Inc
NYSE:RCUS
|
Interest Income Expense
$45m
|
CAGR 3-Years
256%
|
CAGR 5-Years
50%
|
CAGR 10-Years
N/A
|
|
Abbvie Inc
NYSE:ABBV
|
Interest Income Expense
-$1.8B
|
CAGR 3-Years
8%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
-19%
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Interest Income Expense
-$757m
|
CAGR 3-Years
35%
|
CAGR 5-Years
0%
|
CAGR 10-Years
-10%
|
|
Amgen Inc
NASDAQ:AMGN
|
Interest Income Expense
-$2.9B
|
CAGR 3-Years
-44%
|
CAGR 5-Years
-30%
|
CAGR 10-Years
-16%
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Interest Income Expense
$563.1m
|
CAGR 3-Years
78%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Interest Income Expense
$221.8m
|
CAGR 3-Years
-13%
|
CAGR 5-Years
75%
|
CAGR 10-Years
N/A
|
See Also
What is Arcus Biosciences Inc's Interest Income Expense?
Interest Income Expense
45m
USD
Based on the financial report for Mar 31, 2024, Arcus Biosciences Inc's Interest Income Expense amounts to 45m USD.
What is Arcus Biosciences Inc's Interest Income Expense growth rate?
Interest Income Expense CAGR 5Y
50%
Over the last year, the Interest Income Expense growth was 84%. The average annual Interest Income Expense growth rates for Arcus Biosciences Inc have been 256% over the past three years , 50% over the past five years .